Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. hSTING compound 17
- Development stage
- Unknown
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. hSTING compound 17: sourced facts only. name: "The compound 17 showed excellent agonistic activity on hSTING protein in vitro." [PMID:39714832]; target: "The compound 17 showed excellent agonistic activity on hSTING protein in vitro." [PMID:39714832]; developer: "Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China." [PMID:39714832]
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on China Pharma Univ. hSTING compound 17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. hSTING compound 17.